Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research on Ozempic, and Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.
FDA Approval of Lynkuet
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
As a non-hormonal option, Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
New research suggesting Ozempic may reduce biological age.
Author’s summary: New research on Ozempic and FDA approval of Lynkuet.